

## CONTACTS

**Jack Barbut**, CEO

**Luca Bolliger**, Director, Business Development and Communication

## ADDRESS

NovImmune SA  
14 ch. des Aulx  
1228 Plan-Les-Ouates, Geneva  
Switzerland  
www.novimmune.com

## TELEPHONE

+41 22 839 71 41

## FAX

+41 22 839 71 46

## EMAIL

info@novimmune.com

## YEAR FOUNDED

1998  
1999 operational

## FINANCIAL SUMMARY

Private, venture-backed: since inception, NovImmune has raised a total of CHF 154.5 million CHF in 4 major rounds of financing.

Our main investors are:

BZ Bank, Novartis Venture Fund, Ingro Finanz, Varuma, Pictet Private Equity Fund, Aravis Venture Fund.

## COMPANY PROFILE

NovImmune SA ('NovImmune') is a drug discovery and development company with a focus on the development of therapeutic monoclonal antibodies for inflammatory diseases and immune-related disorders. The company is based in Plan-les-Ouates/Geneva, Switzerland.

To date NovImmune has generated seven monoclonal antibodies with the intent to treat immune-related disorders. The pipeline is a balance of preclinical and clinical compounds, specific for clinically validated and novel targets. Each of these portfolio products has the potential of becoming a medicine for multiple medical conditions due to the intrinsic mechanism of action.

Two compounds are in early clinical development with the most advanced in clinical phase II. The lead product, NI-0401/anti-CD3, is currently being tested in Crohn's disease, type 1 diabetes and transplantation. Two more are in preclinical and GMP manufacturing.

## TECHNOLOGY

NovImmune masters three different, established and validated technologies in house:

- The UltiMab system to obtain fully human therapeutic monoclonal antibodies using transgenic mice (technology licensed from Medarex),
- Antibody display selection, that is the selection of fully human antibodies displayed on bacteriophages (technology pioneered and developed by CAT)
- Humanization, that is the grafting of the small sequences responsible for the recognition and binding of the antigen from a non-human species to a fully human mAb backbone

## MANAGEMENT & BOARD OF DIRECTORS

### Senior Management

- Jack Barbut, CEO
- Arnd Christ, CFO
- Marie Kosco-Vilbois, CSO
- Penny Ward, CMO
- Nathalie Muller, HR & admin
- Luca Bolliger, BD & Communication
- Olivia Maurel, Regulatory

### Board of Directors

- Eduard Enrico Holdener, Chairman
- Bernard Mach, Founder and Chairman of SAB
- Jack Barbut, CEO
- Hans-Beat Gürtler, Varuma AG
- Joe Manko, BZ Bank
- Martin Velasco, Chairman of the Board of AC Immune

## PIPELINE

Product	Indication	Research	Pre-Clinical	Phase I	Phase II	Phase III
NI-0401/α-CD3	T1D	██████████	██████████	██████████	██████████	
NI-0401/α-CD3	CD	██████████	██████████	██████████	██████████	
NI-0401/α-CD3	Tx	██████████	██████████	██████████	██████████	
NI-0801/α-IP-10	AIID	██████████	██████████	██████████		
NI-0501/α-IFN <sub>γ</sub>	AIID	██████████	██████████			
NI-0701/α-RANTES	AIID	██████████				
NI-1401/α-IL-17	AIID	██████████				
NI-0101/α-TLR4	AIID	██████████				
NI-1201/α-IL-6Rc	AIID	██████████				

Acronyms:

T1D: Type 1 Diabetes

CD: Crohn's Disease

TX: Transplantation

AIID: Auto-Immune and Inflammatory Diseases